Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson.
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson.
“We’re going to be careful …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bayer surged almost 40% in 2025, ranking among the DAX’s top performers. The rally has pushed its share price close to surpassing…
Megadeals are largely missing in an otherwise healthy M&A environment for biopharma.
Eine Entscheidung aus Amerika treibt den Aktienkurs des Leverkusener Dax-Konzerns. Die Hoffnungen auf ein Ende der…
Milliardensummen hat der Dax-Konzern für die Rechtsstreitigkeiten rund um Glyphosat schon bezahlt. Jetzt geht es in eine…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Pfizer made one thing clear this week: It's officially back in the obesity race.
Lilly, Gilead lead pharma’s M&A boom
